- International families
- 74k2015 to 2024
- Leading country
- United States2.2× the next
- All families
- 218khome filings included
- Over five years
- Rising2020 to 2024 against the five before
Year by year
Patent families by country of origin and the year of the earliest filing, 2000 to 2025; 2025 is a part year, still filling in. International families are those for which protection was sought beyond one country.
Volume
International patent families in the capability, by the year of the earliest filing.
Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google
Share by country
Each country's share of the year's international families, in per cent: the capability's five largest countries of origin, 2015 to 2024, and the rest of the world.
Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google
Country leaderboard
International patent families, 2015 to 2024, by country of origin. Growth compares the latest five full years with the five before.
Ten largest
United States
China
Japan
South Korea
Germany
United Kingdom
Switzerland
France
Canada
Netherlands
31,378
14,103
6,820
3,970
2,703
2,220
1,793
1,697
1,203
1,018
| 2000 to 2025 | ||||||
|---|---|---|---|---|---|---|
| 1 | United States | 31,378 | 42.2% | 1.3× | 37,786 | |
| 2 | China | 14,103 | 19.0% | 2.6× | 140,163 | |
| 3 | Japan | 6,820 | 9.2% | 1.0× | 9,543 | |
| 4 | South Korea | 3,970 | 5.3% | 1.5× | 8,668 | |
| 5 | Germany | 2,703 | 3.6% | 1.0× | 2,872 | |
| 6 | United Kingdom | 2,220 | 3.0% | 1.1× | 2,353 | |
| 7 | Switzerland | 1,793 | 2.4% | 0.9× | 2,000 | |
| 8 | France | 1,697 | 2.3% | 1.0× | 1,780 | |
| 9 | Canada | 1,203 | 1.6% | 1.1× | 1,360 | |
| 10 | Netherlands | 1,018 | 1.4% | 1.1× | 1,202 | |
| 11 | Denmark | 790 | 1.1% | 0.9× | 812 | |
| 12 | Israel | 761 | 1.0% | 1.3× | 973 | |
| 13 | Belgium | 668 | 0.9% | 1.2× | 691 | |
| 14 | Australia | 628 | 0.8% | 1.1× | 652 | |
| 15 | Taiwan | 530 | 0.7% | 1.0× | 809 | |
| 16 | Singapore | 516 | 0.7% | 1.6× | 538 | |
| 17 | Italy | 438 | 0.6% | 1.3× | 476 | |
| 18 | Spain | 436 | 0.6% | 1.4× | 472 | |
| 19 | Sweden | 413 | 0.6% | 1.5× | 437 | |
| 20 | India | 337 | 0.5% | 1.4× | 365 | |
| 21 | Ireland | 211 | 0.3% | 1.0× | 222 | |
| 22 | Austria | 175 | 0.2% | 0.8× | 178 | |
| 23 | Russia | 162 | 0.2% | 1.3× | 872 | |
| 24 | Brazil | 154 | 0.2% | 0.8× | 420 | |
| 25 | Türkiye | 132 | 0.2% | 2.0× | 185 | |
| 26 | Norway | 111 | 0.1% | 1.0× | 114 | |
| 27 | Finland | 94 | 0.1% | 0.8× | 100 | |
| 28 | Portugal | 78 | 0.1% | 1.5× | 88 | |
| 29 | Poland | 72 | 0.1% | 1.3× | 153 | |
| 30 | New Zealand | 72 | 0.1% | 1.1× | 80 | |
| 31 | Cayman Islands | 69 | 0.1% | 0.7× | 75 | |
| 32 | Hong Kong | 65 | 0.1% | 1.8× | 105 | |
| 33 | Hungary | 52 | 0.1% | 1.3× | 65 | |
| 34 | South Africa | 43 | 0.1% | 0.8× | 46 | |
| 35 | Mexico | 35 | 0.0% | 0.5× | 178 | |
| 36 | Czechia | 33 | 0.0% | 1.8× | 67 | |
| 37 | Luxembourg | 21 | 0.0% | 0.2× | 25 | |
| 38 | Saudi Arabia | 20 | 0.0% | 1.2× | 34 | |
| 39 | Malaysia | 16 | 0.0% | 0.1× | 57 | |
| 40 | Liechtenstein | 5 | 0.0% | 0.0× | 5 |
Applicants
The largest applicants by international patent families, 2015 to 2024: across the world, then within each of the five countries with the most families in Synthetic Biology & Genetic Engineering. Names are as held in the source and are not consolidated across subsidiaries.
Global
74,420 international families
UNIV CALIFORNIA · United States
PIONEER HI BRED INT · United States
INST NAT SANTE RECH MED · France
HOFFMANN LA ROCHE · Switzerland
HARVARD COLLEGE · United States
UNIV LELAND STANFORD JUNIOR · United States
1,314
733
607
567
528
512
United States
31,378 international families
UNIV CALIFORNIA
PIONEER HI BRED INT
HARVARD COLLEGE
UNIV LELAND STANFORD JUNIOR
UNIV TEXAS
MASSACHUSETTS INST TECHNOLOGY
1,283
730
526
497
497
486
China
14,103 international families
UNIV JIANGNAN
SHENZHEN INST OF ADV TECH CAS
SHENZHEN BIOCAN TECH CO LTD
BGI SHENZHEN
UNIV TSINGHUA
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD
229
165
147
146
134
132
Japan
6,820 international families
UNIV KYOTO
UNIV TOKYO
UNIV OSAKA
CHUGAI PHARMACEUTICAL CO LTD
KANEKA CORP
FUJIFILM CORP
321
304
275
170
165
162
South Korea
3,970 international families
CJ CHEILJEDANG CORP
SEOUL NAT UNIV R&DB FOUNDATION
KOREA ADVANCED INST SCI & TECH
UNIV KOREA RES & BUS FOUND
KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY
DAESANG CORP
468
202
136
134
107
103
Germany
2,703 international families
BioNTech SE
BASF SE
IMMATICS BIOTECHNOLOGIES GMBH
KWS SAAT SE & CO KGAA
MAX PLANCK GESELLSCHAFT
BOEHRINGER INGELHEIM INT
139
136
109
95
85
82
Similar capabilities
The nine capabilities that share the most international patent families with Synthetic Biology & Genetic Engineering, 2015 to 2024: the families counted in both as a share of those counted in either. Each card shows its five largest countries.
Critical Technology
Advanced Therapeutics, Vaccines & Medical Countermeasures
36.4% shared · 40,220 families in both
United States
China
Japan
South Korea
Germany
35,382
11,223
4,471
4,072
2,767
Critical Technology
Biomanufacturing
28.2% shared · 31,960 families in both
United States
China
Japan
South Korea
Germany
25,142
10,048
9,595
4,747
3,497
Human Capital
Physical Health & Longevity
19.1% shared · 44,900 families in both
United States
China
South Korea
Japan
Germany
77,497
32,383
14,190
14,101
7,671
Critical Technology
Genomics & Biological Data
14.7% shared · 14,676 families in both
United States
China
Japan
South Korea
Germany
17,818
5,444
3,003
2,851
1,616
Human Capital
Nutrition & Preventive Health
5.5% shared · 5,499 families in both
United States
South Korea
China
Japan
Switzerland
7,952
5,251
3,446
3,403
1,203
Production & Innovation
Agrifood & Primary Production
5.3% shared · 10,223 families in both
United States
Japan
China
Germany
South Korea
28,708
17,669
15,613
10,229
9,737
Human Capital
Public Health Functions
4.8% shared · 4,073 families in both
United States
China
Japan
South Korea
Germany
5,511
1,782
1,627
909
600
Strategic Infrastructure
Public Health & Laboratories
3.8% shared · 3,466 families in both
United States
Japan
China
Germany
South Korea
7,163
3,632
2,667
1,475
1,202
Critical Technology
Nuclear Medicine & Radioisotope Technologies
1.1% shared · 965 families in both
United States
China
Japan
Germany
South Korea
4,153
2,013
1,410
792
720
Crosswalk
How Synthetic Biology & Genetic Engineering is matched to the patent classifications. The entries below were chosen for it; each stands for itself and everything beneath it in the scheme, 205 Cooperative entries in all. A patent family counts when any of its codes, in either scheme and at any office, falls under one of them. Codes since retired are placed under the entries that replaced them.
| Entry | Title in the scheme | Why it is chosen | CPC codes | IPC codes | Documents |
|---|---|---|---|---|---|
| C12N15/00 | Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor | Genetic engineering: recombinant DNA, vectors, gene editing | 191 | 105 | 2,684,825 |
| C12N9/22 | Ribonucleases [RNase]; Deoxyribonucleases [DNase] | Nucleases, including gene-editing enzymes | 4 | 1 | 110,255 |
| C12N2310/20 | Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR] | CRISPR nucleic acids | 1 | none | 56,271 |
| C12N5/10 | Cells modified by introduction of foreign genetic material | Genetically modified cells | 6 | 4 | 338,608 |
| A01K67/0275 | Genetically modified vertebrates, e.g. transgenic | Genetically modified animals | 3 | 3 | 56,912 |
CPC and IPC codes are the codes in use on patent documents, at any office, that fall under the entry. Documents is the larger of the two schemes' counts of documents carrying one of them. An entry with no IPC codes can be told apart only in the Cooperative scheme.
The Cooperative codes in use that count towards Synthetic Biology & Genetic Engineering: 205 codes on 2,177,683 documents. The 150 most used are listed; the full list is in the cpc-to-capability.csv download.
| Code | Title | Under entry | How placed | Documents |
|---|---|---|---|---|
| C12N15/86 | Viral vectors | C12N15/00 | In the scheme | 143,671 |
| C12N15/113 | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing | C12N15/00 | In the scheme | 141,147 |
| C12N15/85 | Vectors or expression systems specially adapted for eukaryotic hosts for animal cells | C12N15/00 | In the scheme | 85,099 |
| C12N15/11 | DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity | C12N15/00 | In the scheme | 82,839 |
| C12N15/63 | Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression | C12N15/00 | In the scheme | 71,897 |
| C12N15/70 | Vectors or expression systems specially adapted for E. coli | C12N15/00 | In the scheme | 68,035 |
| C12N9/22 | Ribonucleases [RNase]; Deoxyribonucleases [DNase] | C12N9/22 | In the scheme | 63,741 |
| C12N15/52 | Genes encoding for enzymes or proenzymes | C12N15/00 | In the scheme | 58,479 |
| C12N2310/20 | Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR] | C12N2310/20 | In the scheme | 56,271 |
| C12N15/62 | DNA sequences coding for fusion proteins | C12N15/00 | In the scheme | 52,949 |
| C12N15/111 | General methods applicable to biologically active non-coding nucleic acids | C12N15/00 | In the scheme | 40,614 |
| C12N15/1137 | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes | C12N15/00 | In the scheme | 37,087 |
| C12N9/226 | Class 2 CAS enzyme complex, e.g. single CAS protein | C12N9/22 | In the scheme | 34,636 |
| C12N15/8509 | Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic | C12N15/00 | In the scheme | 33,541 |
| C12N15/09 | Recombinant DNA-technology | C12N15/00 | In the scheme | 32,526 |
| C12N5/10 | Cells modified by introduction of foreign genetic material | C12N5/10 | In the scheme | 30,732 |
| C12N15/907 | Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells | C12N15/00 | In the scheme | 29,808 |
| C12N15/8261 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield | C12N15/00 | In the scheme | 29,310 |
| C12N15/102 | Mutagenizing nucleic acids | C12N15/00 | In the scheme | 28,517 |
| C12N15/1138 | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins | C12N15/00 | In the scheme | 28,439 |
| C12N15/00 | Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor | C12N15/00 | In the scheme | 26,799 |
| C12N15/87 | Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation | C12N15/00 | In the scheme | 26,406 |
| C12N15/81 | Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts | C12N15/00 | In the scheme | 25,823 |
| A01K67/0275 | Genetically modified vertebrates, e.g. transgenic | A01K67/0275 | In the scheme | 24,816 |
| C12N15/10 | Processes for the isolation, preparation or purification of DNA or RNA | C12N15/00 | In the scheme | 24,245 |
| C12N15/74 | Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora | C12N15/00 | In the scheme | 23,870 |
| C12N15/88 | Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle | C12N15/00 | In the scheme | 21,816 |
| C12N15/8286 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance | C12N15/00 | In the scheme | 21,672 |
| C12N15/67 | General methods for enhancing the expression | C12N15/00 | In the scheme | 20,492 |
| C12N15/115 | Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers | C12N15/00 | In the scheme | 19,990 |
| C12N15/8218 | Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS] | C12N15/00 | In the scheme | 19,124 |
| C12N15/8247 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition | C12N15/00 | In the scheme | 17,549 |
| C12N15/8243 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine | C12N15/00 | In the scheme | 17,050 |
| C12N15/8274 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for herbicide resistance | C12N15/00 | In the scheme | 17,048 |
| C12N15/8273 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for drought, cold, salt resistance | C12N15/00 | In the scheme | 16,612 |
| C12N15/8205 | Agrobacterium mediated transformation | C12N15/00 | In the scheme | 16,419 |
| A01K67/0278 | Knock-in vertebrates, e.g. humanised vertebrates | A01K67/0275 | In the scheme | 16,316 |
| A01K67/0276 | Knock-out vertebrates | A01K67/0275 | In the scheme | 15,780 |
| C12N15/8216 | Methods for controlling, regulating or enhancing expression of transgenes in plant cells | C12N15/00 | In the scheme | 15,552 |
| C12N15/90 | Stable introduction of foreign DNA into chromosome | C12N15/00 | In the scheme | 14,597 |
| C12N15/815 | Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces | C12N15/00 | In the scheme | 14,290 |
| C12N15/1003 | Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor | C12N15/00 | In the scheme | 13,759 |
| C12N15/8245 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis | C12N15/00 | In the scheme | 13,565 |
| C12N15/8271 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance | C12N15/00 | In the scheme | 13,142 |
| C12N15/8282 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for fungal resistance | C12N15/00 | In the scheme | 13,004 |
| C12N15/1037 | Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display | C12N15/00 | In the scheme | 12,437 |
| C12N15/1135 | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes | C12N15/00 | In the scheme | 12,097 |
| C12N15/80 | Vectors or expression systems specially adapted for eukaryotic hosts for fungi | C12N15/00 | In the scheme | 11,843 |
| C12N15/1136 | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones | C12N15/00 | In the scheme | 11,705 |
| C12N15/66 | General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease | C12N15/00 | In the scheme | 11,564 |
| C12N15/1093 | General methods of preparing gene libraries, not provided for in other subgroups | C12N15/00 | In the scheme | 11,456 |
| C12N15/8279 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance | C12N15/00 | In the scheme | 11,418 |
| C12N15/8213 | Targeted insertion of genes into the plant genome by homologous recombination | C12N15/00 | In the scheme | 10,633 |
| C12N15/82 | Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs) | C12N15/00 | In the scheme | 10,613 |
| C12N15/8257 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon | C12N15/00 | In the scheme | 9,907 |
| C12N15/1065 | Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags | C12N15/00 | In the scheme | 9,888 |
| C12N15/8289 | Male sterility | C12N15/00 | In the scheme | 9,828 |
| C12N15/902 | Stable introduction of foreign DNA into chromosome using homologous recombination | C12N15/00 | In the scheme | 9,728 |
| C12N15/75 | Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus | C12N15/00 | In the scheme | 9,492 |
| C12N15/79 | Vectors or expression systems specially adapted for eukaryotic hosts | C12N15/00 | In the scheme | 9,427 |
| C12N15/1131 | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses | C12N15/00 | In the scheme | 9,301 |
| C12N15/77 | Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium | C12N15/00 | In the scheme | 9,079 |
| C12N15/01 | Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor | C12N15/00 | In the scheme | 8,999 |
| C12N15/64 | General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host | C12N15/00 | In the scheme | 8,820 |
| C12N15/65 | Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers | C12N15/00 | In the scheme | 8,667 |
| C12N15/1006 | Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers | C12N15/00 | In the scheme | 8,618 |
| C12N15/8241 | Phenotypically and genetically modified plants via recombinant DNA technology | C12N15/00 | In the scheme | 8,533 |
| C12N9/222 | Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes | C12N9/22 | In the scheme | 8,363 |
| C12N15/8251 | Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis | C12N15/00 | In the scheme | 8,053 |
| C12N15/117 | Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs | C12N15/00 | In the scheme | 7,822 |
| C12N15/8275 | Glyphosate | C12N15/00 | In the scheme | 7,657 |
| C12N15/1096 | Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR | C12N15/00 | In the scheme | 7,598 |
| C12N15/1013 | Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads | C12N15/00 | In the scheme | 7,420 |
| C12N15/625 | DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence | C12N15/00 | In the scheme | 7,304 |
| C12N15/1034 | Isolating an individual clone by screening libraries | C12N15/00 | In the scheme | 6,758 |
| C12N5/16 | Animal cells | C12N5/10 | In the scheme | 6,405 |
| C12N15/8283 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for virus resistance | C12N15/00 | In the scheme | 6,036 |
| C12N15/861 | Adenoviral vectors | C12N15/00 | In the scheme | 5,766 |
| C12N15/825 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving pigment biosynthesis | C12N15/00 | In the scheme | 5,288 |
| C12N15/8242 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits | C12N15/00 | In the scheme | 5,268 |
| C12N15/101 | Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase | C12N15/00 | In the scheme | 5,155 |
| C12N15/8201 | Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation | C12N15/00 | In the scheme | 5,146 |
| C12N15/8222 | Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation | C12N15/00 | In the scheme | 5,123 |
| C12N15/8209 | Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers | C12N15/00 | In the scheme | 5,064 |
| C12N15/1086 | Preparation or screening of expression libraries, e.g. reporter assays | C12N15/00 | In the scheme | 4,958 |
| C12N15/635 | Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline | C12N15/00 | In the scheme | 4,875 |
| C12N15/8281 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for bacterial resistance | C12N15/00 | In the scheme | 4,865 |
| C12N15/1058 | Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms | C12N15/00 | In the scheme | 4,844 |
| C12N15/1082 | Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors | C12N15/00 | In the scheme | 4,795 |
| C12N15/746 | Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus) | C12N15/00 | In the scheme | 4,781 |
| C12N15/1017 | Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes | C12N15/00 | In the scheme | 4,771 |
| C12N15/827 | Flower development or morphology, e.g. flowering promoting factor [FPF] | C12N15/00 | In the scheme | 4,655 |
| C12N2015/8518 | Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles | C12N15/00 | In the scheme | 4,553 |
| C12N15/8234 | Seed-specific, e.g. embryo, endosperm | C12N15/00 | In the scheme | 4,136 |
| C12N15/8258 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins | C12N15/00 | In the scheme | 4,135 |
| C12N15/1068 | Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis | C12N15/00 | In the scheme | 4,072 |
| C12N5/163 | Animal cells one of the fusion partners being a B or a T lymphocyte | C12N5/10 | In the scheme | 4,034 |
| C12N15/8285 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance | C12N15/00 | In the scheme | 3,893 |
| C12N15/8278 | Sulfonylurea | C12N15/00 | In the scheme | 3,620 |
| C12N15/1075 | Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass | C12N15/00 | In the scheme | 3,556 |
| C12N15/76 | Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces | C12N15/00 | In the scheme | 3,544 |
| C12N9/224 | Class 1 CAS enzyme complex, e.g. multi-enzyme | C12N9/22 | In the scheme | 3,515 |
| C12N15/867 | Retroviral vectors | C12N15/00 | In the scheme | 3,457 |
| C12N15/1055 | Protein x Protein interaction, e.g. two hybrid selection | C12N15/00 | In the scheme | 3,412 |
| C12N15/8246 | Non-starch polysaccharides, e.g. cellulose, fructans, levans | C12N15/00 | In the scheme | 3,299 |
| C12N5/12 | Fused cells, e.g. hybridomas | C12N5/10 | In the scheme | 3,253 |
| C12N15/89 | Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection | C12N15/00 | In the scheme | 3,225 |
| C12N15/8287 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for fertility modification, e.g. apomixis | C12N15/00 | In the scheme | 3,215 |
| C12N15/1048 | Selex | C12N15/00 | In the scheme | 3,214 |
| C12N15/8645 | Adeno-associated virus | C12N15/00 | In the scheme | 3,104 |
| C12N15/8237 | Externally regulated expression systems | C12N15/00 | In the scheme | 3,077 |
| C12N15/1132 | Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV | C12N15/00 | In the scheme | 3,031 |
| C12N15/1079 | Screening libraries by altering the phenotype or phenotypic trait of the host | C12N15/00 | In the scheme | 2,829 |
| C12N15/8227 | Root-specific | C12N15/00 | In the scheme | 2,767 |
| C12N15/873 | Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos | C12N15/00 | In the scheme | 2,718 |
| C12N15/8214 | Plastid transformation | C12N15/00 | In the scheme | 2,716 |
| C12N15/1027 | Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR | C12N15/00 | In the scheme | 2,713 |
| C12N15/8207 | Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers | C12N15/00 | In the scheme | 2,646 |
| C12N15/8203 | Virus mediated transformation | C12N15/00 | In the scheme | 2,613 |
| C12N15/8238 | Externally regulated expression systems chemically inducible, e.g. tetracycline | C12N15/00 | In the scheme | 2,558 |
| C12N15/1089 | Design, preparation, screening or analysis of libraries using computer algorithms | C12N15/00 | In the scheme | 2,545 |
| C12N15/1031 | Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR | C12N15/00 | In the scheme | 2,437 |
| C12N15/8223 | Vegetative tissue-specific promoters | C12N15/00 | In the scheme | 2,364 |
| C12N15/8206 | Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated | C12N15/00 | In the scheme | 2,363 |
| C12N15/78 | Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas | C12N15/00 | In the scheme | 2,338 |
| C12N15/8277 | Phosphinotricin | C12N15/00 | In the scheme | 2,307 |
| C12N15/8249 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life | C12N15/00 | In the scheme | 2,276 |
| C12N15/8262 | Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield involving plant development | C12N15/00 | In the scheme | 2,230 |
| C12N15/8255 | Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving lignin biosynthesis | C12N15/00 | In the scheme | 2,173 |
| C12N15/8231 | Male-specific, e.g. anther, tapetum, pollen | C12N15/00 | In the scheme | 2,092 |
| C12N15/68 | Stabilisation of the vector | C12N15/00 | In the scheme | 2,086 |
| C12N15/8225 | Leaf-specific, e.g. including petioles, stomata | C12N15/00 | In the scheme | 2,050 |
| C12N15/02 | Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion | C12N15/00 | In the scheme | 1,974 |
| C12N15/1072 | Differential gene expression library synthesis, e.g. subtracted libraries, differential screening | C12N15/00 | In the scheme | 1,908 |
| C12N15/8269 | Photosynthesis | C12N15/00 | In the scheme | 1,885 |
| C12N15/69 | Increasing the copy number of the vector | C12N15/00 | In the scheme | 1,865 |
| C12N15/1062 | Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently | C12N15/00 | In the scheme | 1,858 |
| C12N15/905 | Stable introduction of foreign DNA into chromosome using homologous recombination in yeast | C12N15/00 | In the scheme | 1,809 |
| C12N5/14 | Plant cells | C12N5/10 | In the scheme | 1,771 |
| C12N15/1024 | In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair | C12N15/00 | In the scheme | 1,734 |
| C12N15/8212 | Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid | C12N15/00 | In the scheme | 1,727 |
| C12N15/8221 | Transit peptides | C12N15/00 | In the scheme | 1,723 |
| C12N15/73 | Expression systems using phage (lambda) regulatory sequences | C12N15/00 | In the scheme | 1,713 |
| C12N15/8217 | Gene switch | C12N15/00 | In the scheme | 1,712 |
| C12N15/72 | Expression systems using regulatory sequences derived from the lac-operon | C12N15/00 | In the scheme | 1,673 |
| C12N15/8202 | Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector | C12N15/00 | In the scheme | 1,644 |
| C12N15/71 | Expression systems using regulatory sequences derived from the trp-operon | C12N15/00 | In the scheme | 1,601 |
| C12N2015/8527 | Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases | C12N15/00 | In the scheme | 1,565 |
| C12N15/821 | Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers | C12N15/00 | In the scheme | 1,544 |
| C12N15/8266 | Abscission; Dehiscence; Senescence | C12N15/00 | In the scheme | 1,537 |